Advertisement

Prognostic Factors in Lung Cancer

  • Frank B. Zimmermann
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

Lung cancer is a heterogeneous clinical entity of non-small-cell and small-cell lung cancer types as well as mixed types, with even different clinical behaviors and prognoses within particular pathological subgroups. Current guidelines for treatment decisions in NSCLC and SCLC are based on tumor extension and certain additional clinico-histophatological parameters only. Besides this, numerous clinical laboratory tests and investigations of the cellular, molecular and genetic biology of lung cancer and the environment have been introduced into routine in pathology, clinical chemistry and even nuclear medicine, describing the tumor better than ever before. This knowledge might support the treatment decision, research design and analysis, and may support the development of complex risk models for prediction of lung cancer mortality, and for the selection of an appropriate treatment for each individual case. Unfortunately, countless articles describing more than 150 different prognostic factors but with enormous heterogeneity by interstudy variations, patient selection bias, low number of patients in most trials, retrospective nature of the trials, and poor statistical power may cause confusion. The main purpose of this article with special focus on cancer related, patient related, and environmental aspects is to allow an impression on most important and significant prognostic factors, and to offer a basis for treatment decision in clinical practice concerning patients with small-cell and non-small-cell lung cancer. Most of those factors should not be taken into account for treatment selection, but to carefully use them for stratification in prospective clinical trials. It should always be kept in mind, that the development of new substances in medical oncology, and the improvements in both surgical and radiation oncology increase the therapeutic window, and will change the value of some of the mentioned prognostic factors in near future.

Keywords

Vascular Endothelial Growth Factor Neuron Specific Enolase Lung Cancer Mortality Karnofsky Index Tissue Polypeptide Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CYO (2010) Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) in early-stage (I and II) non-small cell lung cancer (NSCLC). Eur J Nucl Med Mol Imaging 37:691–698PubMedCrossRefGoogle Scholar
  2. Albain KS, Crowley JJ, Leblanc M, Livingston RB (1990) Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 8:1563–1574PubMedGoogle Scholar
  3. Alexander BM, Othus M, Caglar HB, Allen AM (2011) Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 79:1381–1387PubMedCrossRefGoogle Scholar
  4. Al-Saraf N, Gately K, Lucey J, Aziz R, Doddakula K, Wilson L, McGovern E, Young V (2008) Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothor Surg 34:892–897CrossRefGoogle Scholar
  5. Asmis TR, Ding K, Seymour L, Shepherd FA, Leigh NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD (2008) Age and comordidity as independent prognostic factors in the treatment of non small-cell lung cancer. J Clin Oncol 26:54–59PubMedCrossRefGoogle Scholar
  6. Bergh JC (1990) Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes. Am Rev Respir Dis 142:S20–S26PubMedCrossRefGoogle Scholar
  7. Birim O, Kappetein AP, van Klaveren RJ, Bogers AJ (2006) Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 32:12–23PubMedCrossRefGoogle Scholar
  8. Bonnesen B, Pappot H, Homstav J, Guldhammer Skov B (2009) Vascular endothelial growth factor A and vascular endothelial growth factor receptor expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 66:314–318PubMedCrossRefGoogle Scholar
  9. Brambilla E, Travis WD, Colby TV et al (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059–1068PubMedCrossRefGoogle Scholar
  10. Bremnes RM, Sundstrom S, Aasebo U et al (2003) The value of prognostic factors in small cell lung cancer: results from a randomized multicenter study with minimum 5 year follow-up. Lung Cancer 39:303–313PubMedCrossRefGoogle Scholar
  11. Bremnes RM, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51:143–158PubMedCrossRefGoogle Scholar
  12. Brundage MD, Feldman-Stewart D, Cosby R et al (2001) Phase I study of a decision aid for patients with locally advanced non-small cell lung cancer. J Clin Oncol 19:1326–1335PubMedGoogle Scholar
  13. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer. Chest 122:1037–1057PubMedCrossRefGoogle Scholar
  14. Buccheri G (1998) Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur Respir J 11:173–178PubMedCrossRefGoogle Scholar
  15. Buccheri G, Ferrigno D (1994) Prognostic factors in lung cancer: tables and comments. Eur Respir J 7:1350–1364PubMedCrossRefGoogle Scholar
  16. Buccheri G, Ferrigno D (2004) Prognostic factors. Hematol Oncol Clin N Am 18:187–201CrossRefGoogle Scholar
  17. Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A:1135–1141PubMedCrossRefGoogle Scholar
  18. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRefGoogle Scholar
  19. Choi N, Baumann M, Flentje M et al (2001) Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 31:43–56PubMedCrossRefGoogle Scholar
  20. Coate LE, John T, Tsao MS, Shepherd FA (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10:1001–1010PubMedCrossRefGoogle Scholar
  21. Emami B, Perez CA (1993) Lung. In: Perez CA (ed) Radiation oncology. Lippincott, PhiladelphiaGoogle Scholar
  22. Feld R, Borges M, Giner V et al (1994) Prognostic factors in non-small cell lung cancer. Lung Cancer 11(suppl):S19–S23PubMedCrossRefGoogle Scholar
  23. Ferrigno D, Buccheri D, Biggi A (1994) Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J 7:186–197PubMedCrossRefGoogle Scholar
  24. Filosso P, Ruffini E, Asioli S, Giobbe R, Macri L, Bruna MC, Sandri A, Oliaro A (2011) Adensquamous lung carcinomas: a histologic subtype with poor prognosis. Lung Cancer. doi: 10.1016/j.lungcan.2011.01.030
  25. Fissler-Eckhoff A (2010) Prognostic factors in histopatholgy of lung cancer. In: Heide J, Schmittel A, Kaiser D, Hinkelbein W (eds) Controversies in the treatment of lung cancer. Frontier radiation therapy oncology, vol 42. Karger, Basel, pp 1–14CrossRefGoogle Scholar
  26. Fontanini G, De Laurentiis M, Vignati S et al (1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non-small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241–249PubMedGoogle Scholar
  27. Ginsberg RJ, Vokes EE, Raben A (1999) Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott-Raven, Philadelphia, pp 849–950Google Scholar
  28. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA (2011) Non-small-cell lung cancer. Lancet. doi: 10.1016/S0140-6736(10)62101-0
  29. Graziano SL (1997) Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 17:S37PubMedCrossRefGoogle Scholar
  30. Harpole DH, Herndone JE, Young WG et al (1995) Stage I non-small cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 76:787PubMedCrossRefGoogle Scholar
  31. Hespanhol V, Queiroga H, Magalhaes A et al (1995) Survival predictors in advanced non-small cell lung cancer. Lung Cancer 13:253–267PubMedCrossRefGoogle Scholar
  32. Hirsch FR, Matthews MJ, Aisner S et al. (1988) Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 62:973–977PubMedCrossRefGoogle Scholar
  33. Hsu WH, Huang CS, Hsu HS, Huang WJ, Lee HC, Huang BS, Huang MH (2007) Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorax Surg 83:419–424CrossRefGoogle Scholar
  34. Jassem E, Bigda J, Dziadziuszko R et al (2001) Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. Lung cancer 31:17–23PubMedCrossRefGoogle Scholar
  35. Jazieh AR, Hussain M, Howington JA et al (2000) Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg 70:1168PubMedCrossRefGoogle Scholar
  36. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic   (1997) Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 15:893–900PubMedGoogle Scholar
  37. Jeremic B, Shibamoto Y, Nikoloic N et al (1999) Role of Radiation Therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 17:2092–2099PubMedGoogle Scholar
  38. Jeremic B, Classen J, Bamberg M (2002) Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small cell lung cancer. Int J Radiat Oncol Biol Phys 54:119–130PubMedCrossRefGoogle Scholar
  39. Jorgensen LG, Osterlind K, Genollá J et al (1996) Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariate analysis on data from nine centres. Br J Cancer 74:463–467PubMedCrossRefGoogle Scholar
  40. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, Saito R, Kawahara M, Maruyama Y (2010) Gender, histologoy, and time of diagnosis are important factors for prognosis. J Thorax Oncol 5:1011–1017Google Scholar
  41. Kawahara M, Fukuoka M, Saijko N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K, Furuse K (1999) Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 27:158–165CrossRefGoogle Scholar
  42. Komaki R, Fujii T, Perkins P, Ro JY, Allen PK, Mason KA (1996) Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 36:601–605PubMedCrossRefGoogle Scholar
  43. Kwiatkowski DJ, Harpole DH Jr, Godleski JH et al. (1998) Molecular patholgic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 16:2468–2477PubMedGoogle Scholar
  44. Lad T, Piaritadosi S, Thomas P et al (1994) A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small-cell lung cancer to combination chemotherapy. Chest 106:3205–3235Google Scholar
  45. Lamy P, Grenier J, Kramar A, Pujol J (2000) Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 29:197–203PubMedCrossRefGoogle Scholar
  46. Langendijk H, Aaronson NK, de Jong JM et al (2000) The prognostic impact of quality of life assessed with the EORCT QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55:19–25PubMedCrossRefGoogle Scholar
  47. Lebeau B, Chastang C, Schuller MP et al (1995) Chimiothérapie des cancers bronchiques. Importance prognostique d’une résponse complète (1,280 patients). La Presse Médicale 24:217–221PubMedGoogle Scholar
  48. Lebeau B, Urban T, Brechot JM et al (1999) A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small-cell lung cancer. Cancer 86:1480–1487PubMedCrossRefGoogle Scholar
  49. Lee JH, Machtay M, Kaiser LR et al (1999) Non-small cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy. Radiology 213:845–852PubMedGoogle Scholar
  50. Lee DS, Kim YS, Kang JH, Lee SN, Kim YK, Ahn MI, Han DH, Yoo IR, Wand YP, Park JG, Yoon SC, Jang HS, Choi BO (2011) Clinical response and prognostic indicators of concurrent chemoradiation for non-small cell lung cancer. Cancer Res Treat 43:32–41PubMedCrossRefGoogle Scholar
  51. Li CT, Marek M, Guclu SZ, Kin Y, Meshref M, Qin S, Kadziola Z, Krejcy K, Altug S (2011a) Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma. J Cancer 2:52–62PubMedCrossRefGoogle Scholar
  52. Li SH, Tian H, Yue WM, Li L, Li WJ, Chen ZT, Hu WS, Zhu YC, Qi L (2011b) Overexpression of metastasis-associated protein 1 is significantly correlated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. Ann Surg Oncol. doi: 10.1245/s10434-010-1510-5
  53. MacKillop WJ (2001) The importance of prognosis in cancer medicine. In: Gospodarowicz MK, Henson DE, Hutter RBP et al (eds) Prognostic factors in cancer. Wiley, Ney YorkGoogle Scholar
  54. Maione P, Rossi A, Di Maio M, Gridelli C (2009) Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer 66:8–14PubMedCrossRefGoogle Scholar
  55. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR (2006) A prognostic model for advanced stage non small cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 107:781–792PubMedCrossRefGoogle Scholar
  56. Martins SJ, Takagaki TY, Silva AGP, Gallo CP, Silva FBA, Capelozzi VL (2009) Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer 64:105–109PubMedCrossRefGoogle Scholar
  57. Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N (2007) Prognostic value of carcinoembryonic antigen and Cyfra 21-1 in patients with pathological stage I non-small lung cancer. Eur J Cardio Thor Surg 32:435–439CrossRefGoogle Scholar
  58. Meert AP, Paesmans M, Martin B et al (2002) The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87:694–701PubMedCrossRefGoogle Scholar
  59. Micke P, Faldum A, Metz T et al (2002) Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer–What limits limited disease? Lung Cancer 37:271–276PubMedCrossRefGoogle Scholar
  60. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res 41:237–248PubMedCrossRefGoogle Scholar
  61. Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, Kiyotoshi Im Uenishi T, Wakasa K, Suehiro S (2007) Serum Sialyl Lewisx and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung cancer 58:369–375PubMedCrossRefGoogle Scholar
  62. Montazeri A, Milroy R, Hole D et al (2001) Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31:233–240PubMedCrossRefGoogle Scholar
  63. Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111:1710–1717PubMedCrossRefGoogle Scholar
  64. Mountain CF, Lukeman JM, Hammar SP, Chamberlain DW, Coulson WF, Page DL (1987) Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trial population. J Surg Oncol 35:147–156PubMedCrossRefGoogle Scholar
  65. Murray N, Coy P, Pater JL et al (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11:336–344PubMedGoogle Scholar
  66. Murray PV, Soussi T, O’Brian ME et al (2000) Serum p53 antibodies: predictors of survival in small-cell lung cancer? Br J Cancer 83:1418–1424PubMedCrossRefGoogle Scholar
  67. Nakamura H, Taniguchi Y, Miwa K, Adachi Y, Fujioka S, Haruki T, Takagi Y, Yurugi Y (2011) Comparison of surgical outcomes of thoracoscopic lobectomy, segmentectomy, and wedge resection for clinical stage I non-small cell lung cancer. Thorac Cardiov Surg 59:137–141CrossRefGoogle Scholar
  68. Naughton MJ, Herndon JE, Shumaker SA et al (2002) The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study of CALGB 9033. Qual Life Res 11:235–248PubMedCrossRefGoogle Scholar
  69. Olson JR, Robinson CG, El Naqa I, Creach KM, Drzymala RE, Bloc C, Parikh PJ, Bradley JD (2011) Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. doi: 10.1016/j.jrobp.2011.01.038
  70. Osterlind K, Anderson PK (1986) Prognostic factors in small cell lung cancer: a multivariate model base on 778 patients treated with chemotherapy with or without irradiation. Cancer 46:4189–4194Google Scholar
  71. Ou S-HI, Zell JA, Ziogas A, Anton-Culver H (2007) Prognostic factors for survival of stage I nonsmall cell lung cancer patients. Cancer 110:1532–1541PubMedCrossRefGoogle Scholar
  72. Ou S-HI, Zell JA, Ziogas A, Anton-Culver H (2008) Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer 112:2011–2020PubMedCrossRefGoogle Scholar
  73. Ou S-HI, Ziogas A, Zell JA (2009) Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (SNCLC) and is independent of smoking status. J Thorac Oncol 4:1083–1093PubMedCrossRefGoogle Scholar
  74. Paesmans M (2004) Prognosis of small cell lung cancer. In: Sculier JP, Fray WA (eds) Malignant tumors of the lung. Springer, Heidelberg, pp 423–432CrossRefGoogle Scholar
  75. Paesmans M, Sculier JP, Libert P et al (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients: the European Lung Cancer Working Party. J Clin Oncol 13:1221–1230PubMedGoogle Scholar
  76. Paesmans M, Sculier JP, Lecomte J et al (2000) Prognostic factors for patients with small cell lung cancer. Cancer 89:523–533PubMedCrossRefGoogle Scholar
  77. Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M, Scherpereeel A, Munoz VT, Sulier JP (2010) Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer. J Thorac Oncol 5:612–619PubMedGoogle Scholar
  78. Palomares MR, Sayre JW, Shekar KC et al (1996) Gender influence on weight-loss pattern and survival of non-small cell lung carcinoma patients. Cancer 78:2119–2126PubMedCrossRefGoogle Scholar
  79. Pedersen LM, Milman N (1996) Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Resp J 9:1826–1830CrossRefGoogle Scholar
  80. Picardo AL, Diez M, Torres A et al (1996) Analysis of the prognostic significance of cytosolic determination of CA 125, CEA, and SCC in patients with NSCLC. Cancer 77:1066–1072PubMedCrossRefGoogle Scholar
  81. Pujol JL, Quantin X, Jacot W et al (2003) Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 39:131–138PubMedCrossRefGoogle Scholar
  82. Qian Q, Wand Q, Zhan P, Peng L, Wei SZ, Shi Y, Song Y (2010) The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest 28:661–669PubMedCrossRefGoogle Scholar
  83. Quejada MI, Albain KS (2004) Prognostic factors in non-small cell lung cancer. In: Sculier JP, Fry WA (eds) Malignant tumors of the lung. Springer, Heidelberg, pp 405–422CrossRefGoogle Scholar
  84. Quoix E, Purohit A, Faller-Beau M et al (2000) Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 30:127–134PubMedCrossRefGoogle Scholar
  85. Rawson NSB, Peto J (1990) An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 61:597–604PubMedCrossRefGoogle Scholar
  86. Ray R, Quantin X, Grenier J, Pujol JL (1998) Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev 22:293–304PubMedCrossRefGoogle Scholar
  87. Reinmuth N, Brandt B, Semik M, Kunze WP, Achatzy R, Scheld HH, Broermann P, Berdel WE, Macha HN, Thomas M (2002) Prognostic impact of Cyfra21-1 ad other serum markers in completely resected non-small cell lung cancer. Lung Cancer 36:265–270PubMedCrossRefGoogle Scholar
  88. Reinmuth N, Thomas M, Meister M, Schnabel PA, Kreuter M (2010) Current data on predictive markers for anti-angiogenic therapy in thoracic tumours. Eur Respir J 36:915–924PubMedCrossRefGoogle Scholar
  89. Rossi A, Galetta D, Gridelli C (2009) Biological prognostic and predictive factors in lung cancer. Oncology 77(Suppl 1):90–96PubMedCrossRefGoogle Scholar
  90. Rygaard K, Vindelov LL, Spang-Thomsen M (1993) Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts. Int J Cancer 54:144–152PubMedCrossRefGoogle Scholar
  91. Sabiston DCJ, Spencer FC (1995) Surgery of the chest. WB Saunders, PhiladelphiaGoogle Scholar
  92. Salgia R, Skarin AT (1998) Molecular abnormalities in lung cancer. J Clin Oncol 16:1207–1217PubMedGoogle Scholar
  93. Saudners M, Dische S, Barrett A et al (1999) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicentre trial. Radiother Oncol 52:137–148CrossRefGoogle Scholar
  94. Sause W (2001) Nonsurgical management of non-small-cell lung cancer. Hem Oncol Clin N Am 5:277–289CrossRefGoogle Scholar
  95. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P, IASLC International Staging Project (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease as expressed by the 6th edition of the TNM classification of malignant tumours and the proposals for the 7th edition. J Thorac Oncol 3:457–466PubMedCrossRefGoogle Scholar
  96. Sheperd FA, Ginsberg R, Patterson GA et al (1991) Surgical treatment for limited small-cell lung cancer. J Cardiovasc Surg 101:385–393Google Scholar
  97. Shepherd FA, Crowley J, Van Houtte P (2007) The IASLC Lung Cancer Staging Project: proposals regarding the clinical staging of small-cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2:1067–1077PubMedCrossRefGoogle Scholar
  98. Singh S, Parulekar W, Murray N (2005) Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23:850–856PubMedCrossRefGoogle Scholar
  99. Sobin L, Gospdarowicz M, Wittekind C (eds) (2010) TNM classification of malignant tumorus, 7th edn. Blackwell, OxfordGoogle Scholar
  100. Spiegelman D, Maurer LH, Ware JH et al (1989) Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 7:344–354PubMedGoogle Scholar
  101. Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32PubMedGoogle Scholar
  102. Stewart LA, Pignon JP (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909CrossRefGoogle Scholar
  103. Subramanian J, Simon R (2010) What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol 7:327–334PubMedCrossRefGoogle Scholar
  104. Sunaga N, Tsuchiya S, Minato K et al (1999) Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 57:143–148PubMedCrossRefGoogle Scholar
  105. Tai P, Tonita J, Yu E, Skarsgard D (2003) Twenty-year follow-up study of long-term serviva of limited-stage small-cell lung cancer and overview of prognostic and treatment factors. Int J Radiat Oncol Biol Phys 56:626–633PubMedCrossRefGoogle Scholar
  106. Takada M, Fukuoka M, Kawahara M et al (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: results of the Japan Clinical Oncology Group study 9104. J Clin Oncol 20:3054–3060PubMedCrossRefGoogle Scholar
  107. Takigawa N, Segawa Y, Okahara M et al (1996) Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 15:67–77PubMedCrossRefGoogle Scholar
  108. Tamura M, Ueoka H, Kiura K et al (1998) Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Study Group Trials. Acta Med Okayama 52:105–111PubMedGoogle Scholar
  109. Turrisi AT, Kim K, Blum R et al (1999) Twice-daily compared with one-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271PubMedCrossRefGoogle Scholar
  110. Wang CY, Huang MS, Huang MH, Lee HC, Hsu HS (2010) Persistently high serum carcinoembryonic antigen levels after surgery indicate poor prognosis in patients with stage I non-small-cell lung cancer. J Surg Res 163:e45–e50PubMedCrossRefGoogle Scholar
  111. Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890–895PubMedGoogle Scholar
  112. Wheatley-Price P, Le Maitre A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd FA (2010) The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lunge cancer Chemotherapy Trials. J Thorac Oncol 5:640–648PubMedGoogle Scholar
  113. Wigren T, Oksanen H, Kellokumpu-Lehtinen P (1997) A practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol 123:259–266PubMedGoogle Scholar
  114. Willner J, Baier K, Caragiani E et al (2002) Dose, volume, and tumor control predictions in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:382–389PubMedCrossRefGoogle Scholar
  115. Wolf M, Holle R, Hans K et al (1991) Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 63:986–992PubMedCrossRefGoogle Scholar
  116. Work E, Nielson OS, Bentzen SM et al (1997) Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. J Clin Oncol 15:3030–3037PubMedGoogle Scholar
  117. Wu XH, Qian C, Yuan K (2011) Correlations of hypoxia-inducible factor-1α/hypoxia-inducible factor-2α expression with angiogenesis factors expression and prognosis in non-small cell lung cancer. Chin Med J 124:11–18PubMedGoogle Scholar
  118. Würschmidt F, Bünemann H, Heilmann HP (1995) Small cell lung cancer with and without vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys 33:77–82PubMedCrossRefGoogle Scholar
  119. Yip D, Harper PG (2000) Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 28:173–185PubMedCrossRefGoogle Scholar
  120. Zhan P, Wnag J, Lv XJ, Wang Q, Qiu LX, Lin XQ, YuYSong LK, Song Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer. J Thorac Oncol 4:1094–1103PubMedCrossRefGoogle Scholar
  121. Zimmermann FB, Bamberg M, Molls M, Jeremic B (2003) Radiation therapy alone in early stage non-small-cell lung cancer. Semin Surg Oncol 21:91–97PubMedCrossRefGoogle Scholar
  122. Zimmermann F, Wulf J, Lax I, Nagata Y, Timmermann RD, Stojkivski I, Jeremic B (2010) Stereotactic body radiation therapy for early non-small cell lung cancer. In: Heide J, Schmittel A, Kaiser D, Hinkelbein W (eds) Controversies in the treatment of lung cancer. Frontier radiation therapy oncology, vol 42. Karger, Basel, pp 94–114CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg  2011

Authors and Affiliations

  1. 1.University Hospital BaselBaselSwitzerland

Personalised recommendations